Sponsor Dossier
DEMOGEN Pharmaceuticals
Sponsor Dossier for DEMOGEN Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACICLOVIR DEMOGEN
- Brand: AMIKACIN DEMOGEN
- Brand: AMPICILLIN DEMOGEN
- Brand: BENZYLPENICILLIN DEMOGEN
- Brand: CASPOFUNGIN DEMOGEN
- Brand: CEFAZOLIN DEMOGEN
- Brand: CEFEPIME DEMOGEN
- Brand: CEFOXITIN DEMOGEN
About
Demogen Pharmaceuticals is an Australian Private Company with ABN 77681420280, registered in NSW. The entity is active and operates under the trading name DEMOGEN Pharmaceuticals.
Portfolio
DEMOGEN Pharmaceuticals has 26 brands on the ARTG, of which 26 are indexable and 26 carry a Product Information document. 1 brand is PBS-listed, 0 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include ACICLOVIR DEMOGEN, AMIKACIN DEMOGEN, AMPICILLIN DEMOGEN, BENZYLPENICILLIN DEMOGEN, CASPOFUNGIN DEMOGEN, CEFAZOLIN DEMOGEN, CEFEPIME DEMOGEN, CEFOXITIN DEMOGEN, CEFTRIAXONE, CIPROFLOXACIN DEMOGEN, CISATRACURIUM DEMOGEN, DAPTOMYCIN DEMOGEN.
Therapeutic focus
— Infectious Disease: 14 brands — Gastroenterology: 4 brands — Neurology: 2 brands — Endocrinology: 1 brand — Musculoskeletal: 1 brand — Pain Management: 1 brand — Respiratory: 1 brand — Other: 1 brand — Haematology: 1 brand
PBS footprint
1 brand is PBS-listed, with the latest PBS schedule date 2026-11-01.